Nicole J Gormley
Overview
Explore the profile of Nicole J Gormley including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
22
Citations
264
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Baines A, Kanapuru B, Zhao J, Price L, Zheng N, Konicki R, et al.
Clin Cancer Res
. 2024 Oct;
30(24):5515-5520.
PMID: 39412823
On October 25, 2022, the FDA granted accelerated approval to teclistamab-cqyv (TECVAYLI; Janssen Biotech) for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at...
2.
Sarraf Yazdy M, Kasamon Y, Gu W, Rodriguez L, Jin S, Bhatnagar V, et al.
Clin Cancer Res
. 2024 Oct;
30(24):5521-5526.
PMID: 39404868
In April 2023, the U.S. FDA granted regular approval to polatuzumab vedotin-piiq in combination with a rituximab product, cyclophosphamide, doxorubicin, and prednisone (pola+R-CHP) for adult patients who have previously untreated...
3.
Rodriguez L, Gormley N, Lu R, Amatya A, Demetri G, Flaherty K, et al.
Clin Cancer Res
. 2024 Jul;
30(18):3974-3982.
PMID: 39037364
Advances in anticancer therapies have provided crucial benefits for millions of patients who are living long and fulfilling lives. Although these successes should be celebrated, there is certainly room to...
4.
Donaldson J, Seddiq M, Fusco M, Singla S, Pamuk G, Lee-Alonso R, et al.
Cancer Discov
. 2023 Dec;
13(12):2515-2524.
PMID: 38084090
Cancer drug development remained robust in 2023. Highlights of U.S. drug approvals this year include new immunotherapies and targeted drug development in adult and pediatric patients as well as patients...
5.
Telaraja D, Kasamon Y, Collazo J, Leong R, Wang K, Li P, et al.
Clin Cancer Res
. 2023 Aug;
30(1):17-22.
PMID: 37624619
In January 2023, the FDA granted accelerated approval to pirtobrutinib for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL) after at least two lines of...
6.
Howlader N, Sharon E, Bhattacharya M, Ehrlich L, Richardson N, Gormley N, et al.
Cancer Epidemiol Biomarkers Prev
. 2023 Apr;
32(6):744-747.
PMID: 37012203
Introduction: Molecularly targeted therapies such as tyrosine kinase inhibitors (TKI) are effective treatments for B-cell receptor (BCR)-ABL-bearing leukemias. We evaluated the impact of TKIs on historical chronic myeloid leukemia (CML)...
7.
Baines A, Sarraf Yazdy M, Kasamon Y, Ershler R, Jen E, Kanapuru B, et al.
Clin Cancer Res
. 2023 Mar;
29(15):2748-2752.
PMID: 36892497
Minimal residual disease (MRD) is increasingly used as a prognostic biomarker, a measure of clinical efficacy, and a guide for treatment decisions in various hematologic malignancies. We sought to characterize...
8.
FDA Approval Summary: Belantamab Mafodotin for Patients with Relapsed or Refractory Multiple Myeloma
Baines A, Ershler R, Kanapuru B, Xu Q, Shen G, Li L, et al.
Clin Cancer Res
. 2022 Jun;
28(21):4629-4633.
PMID: 35736811
On August 5, 2020, the FDA granted accelerated approval to belantamab mafodotin-blmf (BLENREP; GlaxoSmithKline) for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at...
9.
Maignan K, Fashoyin-Aje L, Torres A, Fernandes L, Gwise T, Baxi S, et al.
Blood Cancer J
. 2022 Apr;
12(4):65.
PMID: 35440047
This retrospective observational study evaluated racial disparities among Black and White patients with multiple myeloma (MM). We included patients from a longitudinal de-identified EHR-derived database who had ≥2 visits recorded...
10.
Anderson K, Auclair D, Adam S, Agarwal A, Anderson M, Avet-Loiseau H, et al.
Clin Cancer Res
. 2021 Jul;
27(19):5195-5212.
PMID: 34321279
The development of novel agents has transformed the treatment paradigm for multiple myeloma, with minimal residual disease (MRD) negativity now achievable across the entire disease spectrum. Bone marrow-based technologies to...